A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjöberg, Folke, Waters, Susanna, Löfberg, Boel, Sonesson, Clas, Waters, Nicholas, Tedroff, Joakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137807/
https://www.ncbi.nlm.nih.gov/pubmed/34018344
http://dx.doi.org/10.1002/prp2.792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137807/
https://www.ncbi.nlm.nih.gov/pubmed/34018344
http://dx.doi.org/10.1002/prp2.792

Ejemplares similares